Bharat Book Bureau

Conference on Anti-Counterfeiting Americas
Best practices for protecting the pharmaceutical supply chain against counterfeiting and fraud
8th - 9th November 2010, Boston, USA

Increasing efforts are being made to protect the national supply chain for medicines distribution. In the US, the pharmaceutical supply chain involves the daily delivery of approximately 13 million prescription products to pharmacies, hospitals, clinics and other healthcare provider locations (Source: Urch Publishing, July 2009).

Visiongain’s Anti-Counterfeiting Americas conference will provide valuable insights, into the latest issues and track and trace packaging technologies shaping the fields of security and supply chain management, with leading experts presenting the best-practices on tackling pharmaceutical counterfeiting and fraud, improving the integrity of distribution channels and relationships between key parties.

By attending the Anti-Counterfeiting Americas conference delegates will gain a comprehensive understanding of this rapidly changing sector, from the complex structure of the supply chain, to the growth in mail order and online pharmacies. The potential for investment in the pharmaceutical logistics market remains high. The FDA has put additional focus on “corporate responsibility” for supply-chain management, and increased vigilance and action is needed due to the rise of counterfeit drugs in the global supply chain. Anti-counterfeiting initiatives discussed include the use of technology-based measures, repackaging, consumer education, and increased collaboration with domestic and international law enforcement agencies.

By attending this conference you will:
• Measure the impact of counterfeit drugs by using a patient centric approach
• Understand the development process necessary to ensure an effective security strategy
• Improve inventory control
• Hear changes in the US FDA and European policies
• Develop global standards to increase patient safety and elevate supply chain integrity
• Learn about leveraging supplier audits throughout a global organization
• Understand the challenges of the global traceability and serialization regulatory environment
• Utilize auto-ID advancements in packaging technologies
• Hear the latest strategies for defending your brand and pursuing offenders
• Develop working relationships with US law enforcement authorities
• Balance the need for tamper-proof packaging with streamlining your supply chain
• Evaluate current methods for the detection of counterfeit medicines
• Be part of a unique networking opportunity

Target Audience:
• Pharmaceutical manufacturing and distributing companies
• Drug wholesalers
• Public health and regulatory bodies
• Legal firms
• Customs and border agencies
• Pharmaceutical packaging and labelling companies
• Anti-counterfeiting technology and service suppliers
• Pharmaceutical specialist couriers
• Anti-counterfeiting organizations
• Contract manufacturing organizations (CMOs)
• Retail pharmacy chains
• Non-governmental healthcare organizations and Academia

Who should attend:

Chief Security Officers, VPs, directors, heads, managers and specialists of:
• Supply chain/ Supply Chain Security/ Supply Chain Systems/ Global Supply Chain
• Anti-counterfeit Projects / Anti-counterfeiting Operations
• Distribution/ Logistics
• Security/ Global Security
• Packaging & Labelling
• Brand Protection
• Legal Counsel
• Regulatory Affairs/ Intellectual Property
• Quality Assurance/ Quality Control
• Compliance
• Information systems

Day 1
Anti-Counterfeiting Americas
Monday 8th November 2010

09:00 Registration and refreshments
09:30 Opening address from the chair
Lorne M Lipkus
Partner
Kestenberg Siegal Lipkus LLP
09:40 The business value of product serialization within the pharmaceutical supply chain
Across the U.S. pharmaceutical supply chain, organizations are aligning themselves to enable more effective product serialization and increased visibility using new standards. With widespread serialization comes tremendous opportunity for pharmaceutical manufactures and their trading partners to leverage new standards for increased efficiency and greater ROI. In this session, the GS1 Healthcare US organization, the US implementation arm of the leading standards-setting body for product identification, illustrates the business value of serialization and pedigree/visibility information.
• GS1 EPCIS standard as a pathway to significant potential business value
• The status of adoption of GLN and GTIN in pharma
• The industry status for using serial data to match product
• How serialization can provide enormous visibility into the supply chain
• Update on the 2015 readiness program (preparing for serialization and pedigree within the US)
Robert Celeste
Director, Healthcare
GS1 US
10:20 Forging strategic partnerships to elevate
product integrity
• Industry trends
• Developing and applying a risk management process
• Assessing qualifications
• Transitioning a qualified vendor into a strategic partner
• Case study
Mike Lewis
Business Development Manager
Sentry BioPharma Services
11:00 Morning refreshments
11:20 Securing pharmaceuticals against counterfeiting: Assessing latest protection technologies
• Latest developments in anti-counterfeiting technologies
• Packaged-bases vs on-product solutions
• Designing a comprehensive anti-counterfeiting strategy
Frank Schurgers
Managing Director
Integris

12:00 Counterfeiting in developing countries: The use of mixed technology
• External control in massive consume products
• The ‘umbrella brand’ concept: The perfect attack
• Internal control in massive consumer products
• The colombia case
• Results and real benefits
Andres Diaz Cote
President
Figurazione
12:40 Networking lunch
13:40 Protecting IP rights
• Trademarks and identity preservation
• History of branding and quality assurance
• Causes of counterfeiting
• Anti-counterfeiting technology and choice
14:20 Track and Trace at the WIP manufacturing level
• Overview for analyzing tradeoffs between brand protection technologies
• Why is information regarding authentication of products and their movement critical?
• “Pre-adaption” of pharmaceutical manufacturers to incorporate brand authentication as an integral part of their existing operations
Jim Williams
Founder & Chief Scientist
Polyonics
15:00 Afternoon refreshments
15:20 Illegal internet pharmacies: A framework for coordinated action and cooperation
• Illegal internet pharmacies: Extent of the problem
• Action against illegal internet pharmacies: What has been done?
• What remains to be done: The need for additional action
16:00 Supporting safe medicines strategies in
developing countries
• Which developed countries are the most susceptible destination markets for counterfeit drugs?
• Assessing the scale and economic cost of counterfeiting
• Discuss the role of drug regulations and law enforcement
• Cooperation with national & international agencies
Tom Woods
President
Woods International
16:40 Closing remarks from the chair

16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2
Anti-Counterfeiting Americas
Tuesday 9th November 2010

09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Cost-effective anti-counterfeiting solutions for the second tier
• Repackaging and counterfeiting
• Technologies
• Evaluate packaging-based and product-based anti-counterfeiting measures by cost, complexity, and effectiveness for second tier products
Sharon Flank
CEO
InfraTrac
10:20 Protecting medicines from diversion and counterfeiting
• A multi-layered approach for brand protection
• Specialty distribution as a tool for combating diversion
• Using smartphones and mobile phones in brand integrity and
loyalty programs
Steve Wood
President & CEO
Covectra
11:00 Morning refreshments
11:20 Combating pharmaceutical anti-counterfeiting from a legal perspective
• Relationship between parallel trade and counterfeiting
• Basic framework for the parallel trade of pharmaceuticals
• Recent and future developments
12:00 Balancing the need for tamper-proof packaging with streamlining your supply chain
• Cost to manufacturers
• Choosing the right tamper-evident packaging for your product
• The smarter supply chain of the future
12:40 Networking lunch

13:40 Detecting pharmaceutical counterfeiting
• Stages of investigation
• Investigation and detection of contamination in pharmaceutical products
• QC and GMP techniques
Philip Payne
Investigative Partner
RSSL
14:20 Case study: Utilizing forensic analysis in support of counterfeit investigations
The presentation will look at various strategies to utilize forensic evidence for carrying out counterfeit investigations
Vaughn Volpi
President
PICA
15:00 Afternoon refreshments
15:20 The global impact of fake medicine
• Overview of the counterfeit drugs: Some examples
• How fake medicines harm patients and public
• Building a Coalition: A call to action
Scott LaGanga
Executive Director
Partnership for Safe Medicines
16.00 Protecting profits and patient safety through implementing new technologies
• Preventative technologies
• Authentication technologies
• Track & Trace technologies
16:40 Chair’s closing remarks
16:50 End of conference

For more please visit
http://www.bharatbook.com/detail.asp?id=141389&rt=Conference-on-Anti-Counterfeiting-Americas-Conference-and-workshop.html

OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Choices in Cord Blood Banking Factors Influencing Parental Decision Making

Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as ¡§minimally informed.¨

Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the cord blood banking industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents throughout the U.S., as well as Canada, Mexico, Europe, Asia, South/Central America, Australia and other regions answered the detailed survey between November 2008 and January 2009.
The report includes:

Sources through which expectant parents learn of cord blood banking
Rates of parental awareness of cord blood banking by gender, household income, geographic location, education, birth order, and other critical factors
Reasons parents cite as driving the decision to store cord blood
Factors influencing the decision for private vs. public storage of cord blood
Price sensitivity and quality expectations
Comparative analysis of quality variables among cord blood banks and parent perceptions of them
Parental responsiveness to health statistics
Differences in perspective based on global region, as well as differences due to location (city vs. suburban vs. rural)
Critical trends in cord blood banking and the factors influencing them
Competitive analysis of the Cord Blood Banking Industry, including:

U.S. Public Cord Blood Banks
U.S. Private Cord Blood Banks
International Public Cord Blood Banks
International Private Cord Blood Banks
Population Profiling: Characteristics of those highly/moderately/least likely to purchase cord blood banking services

Methods to effectively communicate with your target audience: Expectant Parents
And much more…

Table of Contents:

PART 1: CORD BLOOD BANKING, INDUSTRY OVERVIEW
I. Abstract
II. Cord Blood Stem Cells

A. Fetal Cord Blood Characteristics

B. Existing Treatments

C. Future Applications

III. Cord Blood Banking Industry

A. History

B. Private vs. Public Cord Blood Banks

1. U.S. Public Banks

a. Overview

b. Number of Public Banks

c. Geographic  Distribution

2. U.S. Private Banks

a. Overview

b. Number of U.S. Private Banks

c. Geographic  Distribution

3. Free Programs for U.S. Families with Medical Need

4. International Banks

a. Overview

b. Number Private Cord Blood Banks by International Region

IV. Market Characterization

A. List of U.S.  Private Cord Blood Banks

B. List of U.S. Public Cord Blood Banks

C. U.S. Mail-In Donation Cord Blood Banks

D. Breakdown of Canadian Cord Blood Banks – Public vs. Private / AABB Accredited vs. Non-Accredited

E. International Cord Blood Banks

1. Mexican Cord Blood Banks

a. Private Banks

b. Public Banking System

2. South/Central American Cord Blood Banks

a. Private Banks

b. Public Banking System

3. United Kingdom Cord Blood Banks

a. Private Banks

b. Public Banking System

4. European Cord Blood Banks

a. Private Banks

b. Public Banking System

5. Middle Eastern Cord Blood Banks

a. Private Banks

b. Public Banking System

6. Indian Cord Blood Banks

a. Private Banks

b. Public Banking System

7. Asian Cord Blood Banks

a. Private Banks

b. Public Banking System

8. Australian / New Zealand Cord Blood Banks

a. Private Australian and New Zealand Cord Blood Banks

b. Public Cord Blood Banks by Australian State

i. New South Wales

ii. Victoria

iii. Queensland

iv. Western Austalia, South Australia, & Tasmania

9. African Cord Blood Banks

a. Private Banks

b. Public Banking System

F. List of International Public Cord Blood Banks (Alphabetical by Country)

G. Worldwide List of AABB Accredited Cord Blood Facilities

V. United States Cord Blood Banking Legislation

A. U.S. State

B. U.S. Federal

1. Institute of Medicine Recommendations Study

a. Overview

b. Key Recommendations

c. IOM Study Shapes National Public Health Policy

2. Presidential Executive Order Expanding Approved Stem Cell Lines in Ethically Responsible Ways

a. Background

b. The Order

3. The Stem Cell Therapeutic and Research Act of 2005

a. Background

b. Current Status of the Act

VI. International Analysis – Trends, Policies and Industry Conditions (by Country)

A. NORTH & SOUTH  AMERICA

1. Canada

2. Mexico

3. United States

4. Brazil

5. Chile

6. Colombia

B. ASIA

1. China

2. Japan

3. Korea

4. Malaysia

5. Taiwan

6. Singapore

7. Thailand

C. INDIA

D. AUSTRALIA & NEW ZEALAND

E. EUROPE

1. European Union

a. Policy Overview

b. NETCORD Foundation

2. France

3. Germany & Austria

4. Italy

5. Netherlands

6. Spain

7. Poland

8. Russian Federation

9. United Kingdom

VII. Cost Analysis: Cord Blood Banking

A. Reasons for Variation in Cord Blood Pricing

1. Companies have Flexibility in the Pricing that they Set

2. Companies have Variables in the Services that they Offer

3. Variable Fee Breakdowns

B. Range of Pricing for U.S. Cord Blood Companies (1-100th percentiles)

1. U.S. Cord Blood Banking Price Range (1-100th%)

2. Lowest U.S. Pricing

3. Highest U.S. Pricing

4. Average U.S. Cord Blood Costs (25-75th percentiles)

5. Median Cost of U.S. Storage (50% percentile)

C. Range of Pricing for Canadian Cord Blood Companies (1-100th percentiles)

1. Canadian Cord Blood Banking Price Range (1-100th%)

2. Lowest Canadian Pricing

3. Highest Canadian. Pricing

4. Average Canadian. Cord Blood Costs (25-75th percentiles)

5. Median Cost of Canadian Storage (50% percentile)

VIII. Comparative Analysis of Quality Variables

A. Technical Variables

1. Vapor-Phase Storage vs. Liquid-Phase Storage

2. Cryo-bags vs. Cryo-vials

3. Pentastarch vs. Hetastarch

4. Computer Controlled vs. Manual Rate Freezing

5. Whole Sample vs. Volume Reduction

6. High-Control vs. Low-Control Aseptic Processing

B. Corporate Variables

1. Corporate Stability

2. Scientific Expertise

PART 2: EXPECTANT PARENTS, SURVEY RESULTS & FINDINGS

I. Survey Overview

A. Survey Population

B. Characterization of Market Survey Respondents

1. Geographic Distribution of Market Survey Respondents

2. Household Income Distribution of Survey Respondents

a. All Respondents

b. U.S. Respondents

3. Respondent Breakdown by Race

4. Respondent Breakdown by Gender

5. Respondent Breakdown by Level of Education

6. Respondent Breakdown by Location (City vs. Suburban vs. Rural)

7. Regional Breakdown of U.S. Respondents

8. Demographic Conclusions

II. Rates of Awareness: Unaware / Minimally Informed / Moderately Informed / Knowledgeable

A. Overall

B. By Gender

C. By Household Income

1. All Respondents

2. U.S. Respondents

D. By Education

E. By Race

F. By Geographic Location

1. Region within U.S.

2. Location (City vs. Suburban vs. Rural)

G. By Number of Existing Children within Family (e.g. Birth Order)

III. Factors Influencing Awareness

A. Personal Exposure: Relative Impact of Family, Co-Workers, Peers

B. Informational Sources: Information Sites, Books Medical Pamphlets, Government Sources

C. Medical Exposure: General Doctors, Ob / Gyn, Midwifes, Nurse, Other

D. Promotional Sources:  Internet Advertisements, Print Advertisements, Radio, TV, Other

IV. Factors Influencing Parental Decision-Making

A. Factors Influencing the Decision Not to Store Cord Blood

1.  Knowledge Level

2.  Price Sensitivity

3.  Safety Concerns

4.  Lack of Access

5.  Misconceptions

B. Factors Influencing the Decision for Private vs. Public Storage of Cord Blood

1. Ethical Beliefs

2. Gender

3. Total Household Income

4. Level of Education (Highest Level Achieved by at Least One Parent)

5. Race

6. Geographic Location

a. Region within U.S.

b. City vs. Suburban vs. Rural

7.  Access to Reliable Healthcare

8.  Number of Existing Children within Family (Birth Order)

9.  Source of Knowledge

10. Perceived Support of Medical Staff

11. Family Medical History

C. International Analysis of Cord Blood Banking Perceptions (Region-by-Region)

V. Parental Responsiveness to Health Statistics

A.  Overview

B.  Health Statistics

C.  Health Statistic Conclusions

VI. Parental Expectations

A. Quality of Services

B. Willingness to Educate/Inform

C. Reputability of Organization

VII. Trends

A. Rates of Cord Blood Storage (units per year)

B. Rates of Parental Awareness

C. Cord Blood Research Publication Rates

D. Cord Blood Research Funding Levels

E. Cord Blood Patent Breakdown

F.  Rates of Cord Blood Research Product Development

VIII. Informative Websites: Online Sources Utilized by Expectant Parents

A. Overview of Websites

1. Information Only

2. Commercial Affiliation

B. Dominant Regional Websites (International Analysis)

C. Most Important Criteria Used to Identify Sites to Inform Decision-Making

D. Underlying Reasons for Visiting Online Resources

IX. Conclusions

A. Traits of a “Model Customer”

1. “Model Customer” for a Private Cord Blood Bank

2. “Model Customer” for a Public Cord Blood Bank

B. Ideal Price Range

C. Approaches for Communicating with Expectant Parents

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Choices-in-Cord-Blood-Banking-Factors-Influencing-Parental-Decision-Making.html

Home healthcare, also referred to as formal or skilled care, is the support and care service that healthcare professionals provide at the patient’s own home. These care services include respiratory therapy, home infusion therapy, home medication, skilled nursing or medical care. The global home care and self care market is the aggregate of the markets for home healthcare equipment and home healthcare services.

The most important trend in healthcare witnessed in the recent times has been a shift of patient’s focus from hospitals to home care. The move from treatment to proactive monitoring has opened up new opportunities in the home healthcare market. Patients prefer home healthcare over hospitals mainly for the latter’s cost and convenience benefits; and are thus increasingly opting for third-party medical professionals and care-givers.

The home healthcare market generates approximately 70% of revenues from the people aged 65 years and above; mainly because of the declining ‘elderly support ratio’, or the ratio of the number of people caring for the elderly, to the number of older people above 65 years. This factor highlights the growth potential of the market for third-party care in the coming years.

Market Estimates and Forecast
The report provides in-depth market estimates and forecasts for the global home healthcare market as follows:

• Home Healthcare Equipment
Home therapeutic equipment (oxygen delivery systems, CPAP, nebulizers, ventilators, humidifiers, IV diagnostics, home dialysis, ostomy supplies, and others)
Home self diagnostics and patient monitoring equipment (diabetes care including blood glucose monitors, test strips, and insulin delivery devices; blood pressure monitors, holter monitors, heart rate meters, apnea and sleep monitors, and others)
Mobility assist devices (wheelchairs, walkers, crutches, canes, walking sticks, examination chairs, treatment chairs, medical beds, ENT devices and other medical furniture and accessories)

• Home Healthcare Services
Home respiratory therapy services
Home infusion therapy services
Home visits and nursing care services (physical examination, physical therapy, nursing services)
Home telemedicine services

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments.

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
- No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW.
- We provide 10% customization. Research shows that more than 40% of the times, clients do not get the specific intelligence they need in multi-client market research reports. We offer 10% customization in our reports at no extra cost. Get the exact market intelligence you require with real value for money.
- 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Home-Healthcare-Market.html

Asia medical tourism industry has been growing with a double digit CAGR and expected to reach US$ 8.5 Billion by 2013. Thailand and India vie with each other for the medical tourism crown. Thailand’s prices are a bit higher on average than India’s, with the main advantages being a better overall tourist experience and more bundling of services. In 2008 Thailand has treated the highest number of international patients compared to any other Asian countries. But its market share of Asia medical tourist arrivals and medical tourism market is declining year on year is a matter of concern.

India advantages are that it is the cheapest of any of the world medical tourism destinations, while being the equal of the other major destinations in terms of quality of staff, equipment and healthcare procedures. With many brand new state of the art hospitals and western trained doctors it is easy to see why it is a leader in medical tourism. In 2008 India market shares in Asia medical tourist arrivals was 18.7 percent and it is expected to rise further to nearly 25 percent by 2013.

However, these two major players are getting tough competitions from other Asian countries like Philippines, Singapore, Malaysia and South Korea. All these have government-backed medical tourism programs and are trying to catch up fast. Singapore is planning to be developed into a leading health care destination in Asia with its medical tourism market steady growth of 11.9 percent over the past few years (2004 to 2008).

In comparison to this South Korea is planning to develop an island into a healthcare hub with all the latest healthcare facilities by 2011. The island will be a two-hour flight from five major Asian cities Seoul, Beijing, Shanghai, Hong Kong and Tokyo. Malaysia is concentrating on neighboring countries like Indonesia Singapore for its growth going forward. The international patient arrivals to Malaysia are expected to grow with a CAGR of 29.27 percent for the period of 2009 to 2013.

“Asia Medical Tourism Analysis (2008 – 2013)” provides detailed analysis about the past, present and future outlook of medical tourism in Asia. Six Asian countries (India, Malaysia, Philippines, Thailand, Singapore, and South Korea) markets have been covered in this report. Each country markets has been analyzed from the point of medical tourist arrivals, medical tourism market, cost of medical treatment, patient perceptions, driving forces of that market, and roadblocks (challenges) to the market. This report provides valuable information to clients looking to venture into these markets and helps them to advise strategies while going for an investment in these markets. This report will help Investment Bankers, Research Analyst, Management Consultants, Researchers, Wealth Managers etc. to have access to the latest trends and recent developments in medical tourism industry.

Research Highlights

• India offers the cheapest medical treatment in comparison to other Asian medical destination.
• India is forecasted to treat the second highest number of medical tourist in 2013 after Thailand.
• Introduction of cosmetic surgery tax in 2009 by Indian government puts India on the disadvantages position compared to other Asian countries.
• In 2007 more than 70 percent of medical tourists visiting Malaysia were of Indonesian origin.
• Medical tourist arrival in Singapore was 15 percent less in 2007 compared to 2006.
• Thailand is forecasted to have the highest number of medical tourist among other Asian countries by 2013.
• By 2011, South Korea is planning to develop an island for medical tourism with an investment of US$ 315 Million having all types of healthcare facilities. The island is only a two-hour flight from five major cities Seoul, Beijing, Shanghai, Hong Kong and Tokyo.
• South Korea has opened one-stop service center for medical travelers like establishing of information booths and medical information website in five languages.
• South Korea government has allowed foreign investors (individual and institutional) to operate hospitals in the country’s free economic zones (FEZs).

Key Players

This section provides the overview and key financials of prominent players in the Asian medical tourism markets, such as Apollo, Bumrungrad, Raffles and Parkway Health.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.

Table of Contents:

1. Executive Summary
2. Why Medical Tourism is Growing?
2.1 The Role of Cost and Quality
2.2 Proactive role of Asian Governments
2.3 The Internet and the International Patient
2.4 Link between Insurance firms & Employers
2.5 Accreditations
2.5.1 Joint Commission International (JCI)
2.5.2 Trent Accreditation Scheme (TAS)
2.5.3 International Organization for Standardization (ISO)
2.5.4 Regional Accreditation Organizations
3. Asia - Medical Tourism
3.1 Past & Present Scenario
3.1.1 Medical Tourist Arrivals
3.1.2 Medical Tourism Market
3.2 Future Forecast
3.2.1 Medical Tourist Arrivals
3.2.2 Medical Tourism Market
3.3 Clinical Market Segmentation
3.3.1 Cardiac/Heart Surgery
3.3.2 Orthopedic Surgery
3.3.3 Neurological & Spinal Surgery
3.3.4 Dental Tourism
3.3.5 Cosmetic/Plastic Surgery
4. Geographical Distribution
4.1 India
4.1.1 Medical Tourist Arrivals
4.1.2 Medical Tourism Market
4.1.3 Market Drivers
4.1.3.1 Large English Speaking Population
4.1.3.2 Cheapest of all Medical Tourist Destinations
4.1.3.3 Commonwealth Games to generate Billions for India Medical Tourism
4.1.4 Roadblocks
4.1.4.1 New Cosmetic Surgery Tax in India to hit Medical Tourism hard
4.2 Malaysia
4.2.1 Medical Tourist Arrivals
4.2.2 Medical Tourism Market
4.2.3 Market Drivers
4.2.3.1 State of the Art Healthcare Facilities at Competitive Price
4.2.3.2 Affordable and Easy Accommodation
4.2.3.3 Tourism - The Best Part of Medical Tourism in Malaysia
4.2.4 Roadblocks
4.2.4.1 Epidemic Fears
4.2.4.2 Economic Slowdown
4.3 Philippines
4.3.1 Medical Tourist Arrivals
4.3.2 Medical Tourism Market
4.3.3 Market Drivers
4.3.3.1 Low Cost & English Speaking Population
4.3.3.2 Strong Government Support
4.3.4 Roadblocks
4.3.4.1 Lack of Accredited Hospital and Stringent Regulations
4.3.4.2 Long Distances from North America & Europe
4.4 Thailand
4.4.1 Medical Tourist Arrivals
4.4.2 Medical Tourism Market
4.4.3 Market Drivers
4.4.3.1 Biggest Asian Medical Tourist Destination
4.4.3.2 Among Biggest Spa Destinations in World
4.4.4 Roadblocks
4.4.4.1 Politically Unstable State
4.5 Singapore
4.5.1 Medical Tourist Arrivals
4.5.2 Medical Tourism Market
4.5.3 Market Drivers
4.5.3.1 Strong Reputation & No Language Barrier
4.5.3.2 Strong Government Support & Stringent Healthcare Laws
4.5.4 Roadblocks
4.5.4.1 Higher Charges than other Asian Countries
4.6 South Korea
4.6.1 Medical Tourist Arrivals
4.6.2 Medical Tourism Market
4.6.3 Market Drivers
4.6.3.1 Island to be turned into Resort-Style Medical Tourism Centre
4.6.3.2 Providing One-stop Service for Medical Tourism
4.6.3.3 Relaxed Foreign Ownership to boost Medical Travel Industry
4.6.4 Roadblocks
4.6.4.1 Language & Cultural Barriers
5. Key Players
5.1 Apollo Hospitals Enterprise Ltd.
5.2 Bumrungrad Hospital Public Co. Ltd.
5.3 Raffles Medical Group
5.4 Parkway Holdings Ltd.

List of Figures:

2 1: Asia - Cost of Various Surgeries (Heart Bypass, Heart Valve Replacement, Angioplasty, Hip Replacement, Hysterectomy & Knee Replacement) in US, India, Thailand & Singapore (in US$)
3 1: Asia - Cost of Various Surgeries (Heart Bypass, Heart Valve Replacement & Angioplasty) in US, India, Thailand, Singapore & South Korea (in US$)
3 2: Asia – Cost of Artery Bypass Surgery in UK & India (in Pound)
3 3: Asia - Cost of Various Surgeries (Total Hip Replacement & Knee Replacement) in US, UK, India, Thailand, Singapore & South Korea (in US$)
3 4: Asia - Cost of Neurological & Spinal Surgery in UK & India (in US$)
3 5: India - Cost of Dental Treatments in US & India (in US$)
3 6: Asia – Cost of Cosmetic Surgery in US, Canada, India, Thailand & South Korea
4 1: Singapore – Healthcare Facilities (in number), 2005 – 2007
4 2: Singapore – Medical Procedure Costs in Comparison to Other Countries (US, India, Thailand & Costa Rica

List of Charts

3 1: Asia – Medical Tourist Arrivals (in Numbers), 2005 – 2008
3 2: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Medical Tourist Arrivals (in Percent), 2005 – 2008
3 3: Asia – Medical Tourism Market (in Million US$), 2006 – 2008
3 4: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Medical Tourism Market (in Percent), 2006 – 2008
3 5: Asia – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
3 6: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Forecast for Medical Tourist Arrivals (in Percent), 2009 – 2013
3 7: Asia – Forecast for Medical Tourism Market (in Million US$), 2009 – 2013
3 8: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Forecast for Medical Tourism Market (in Percent), 2009 – 2013
4 1: India – Medical Tourist Arrivals (in Numbers), 2002 – 2008
4 2: India – Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 3: India – Medical Tourism Market (Million US$), 2002 – 2008
4 4: India – Medical Tourism Market (Million US$), 2009 – 2013
4 5: Malaysia – Medical Tourist Arrivals (in Numbers), 2003 – 2008
4 6: Malaysia – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 7: Malaysia – Medical Tourism Market (Million MYR), 2003 – 2008
4 8: Malaysia – Forecast for Medical Tourism Market (Million MYR), 2009 – 2013
4 9: Malaysia – Country wise Medical Tourist Arrivals (in Percent), 2007
4 10: Philippines – Medical Tourist Arrivals (in Numbers), 2007 – 2008
4 11: Philippines – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 12: Philippines – Medical Tourism Market (Million US$), 2007 – 2008E
4 13: Philippines – Forecast for Medical Tourism Market (Million US$), 2003 – 2008
4 14: Thailand – Medical Tourist Arrivals (in Million), 2005 – 2008E
4 15: Thailand – Forecast for Medical Tourist Arrivals (in Million), 2009 – 2013
4 16: Thailand – Medical Tourism Market (Billion Baht), 2005 – 2008E
4 17: Thailand – Forecast for Medical Tourism Market (Billion Baht), 2009 – 2013
4 18: Singapore – Medical Tourist Arrivals (in Thousands), 2004 – 2008E
4 19: Singapore – Forecast for Medical Tourist Arrivals (in Thousands), 2009 – 2013
4 20: Singapore – Medical Tourism Market (Million US$), 2004 – 2008E
4 21: Singapore – Forecast for Medical Tourism Market (Million US$), 2009 – 2013
4 22: South Korea – Medical Tourist Arrivals (in Numbers), 2005, 2007 – 2008
4 23: South Korea – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2015
4 24: South Korea – Medical Tourism Market (Million US$), 2006 – 2008E
4 25: South Korea – Forecast for Medical Tourism Market (Million US$), 2009 – 2015
4 26: South Korea – Government & Private Sector Investment in Healthcare Town of Jeju Free International City Development Center (in Million US$ & Percent)

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Asia-Medical-Tourism-Analysis-2008-%E2%80%93-2013.html

Asia Medical Tourism Analysis

Asia medical tourism industry has been growing with a double digit CAGR and expected to reach US$ 8.5 Billion by 2013. Thailand and India vie with each other for the medical tourism crown. Thailand’s prices are a bit higher on average than India’s, with the main advantages being a better overall tourist experience and more bundling of services. In 2008 Thailand has treated the highest number of international patients compared to any other Asian countries. But its market share of Asia medical tourist arrivals and medical tourism market is declining year on year is a matter of concern.

India advantages are that it is the cheapest of any of the world medical tourism destinations, while being the equal of the other major destinations in terms of quality of staff, equipment and healthcare procedures. With many brand new state of the art hospitals and western trained doctors it is easy to see why it is a leader in medical tourism. In 2008 India market shares in Asia medical tourist arrivals was 18.7 percent and it is expected to rise further to nearly 25 percent by 2013.

However, these two major players are getting tough competitions from other Asian countries like Philippines, Singapore, Malaysia and South Korea. All these have government-backed medical tourism programs and are trying to catch up fast. Singapore is planning to be developed into a leading health care destination in Asia with its medical tourism market steady growth of 11.9 percent over the past few years (2004 to 2008).

In comparison to this South Korea is planning to develop an island into a healthcare hub with all the latest healthcare facilities by 2011. The island will be a two-hour flight from five major Asian cities Seoul, Beijing, Shanghai, Hong Kong and Tokyo. Malaysia is concentrating on neighboring countries like Indonesia Singapore for its growth going forward. The international patient arrivals to Malaysia are expected to grow with a CAGR of 29.27 percent for the period of 2009 to 2013.

“Asia Medical Tourism Analysis (2008 – 2013)” provides detailed analysis about the past, present and future outlook of medical tourism in Asia. Six Asian countries (India, Malaysia, Philippines, Thailand, Singapore, and South Korea) markets have been covered in this report. Each country markets has been analyzed from the point of medical tourist arrivals, medical tourism market, cost of medical treatment, patient perceptions, driving forces of that market, and roadblocks (challenges) to the market. This report provides valuable information to clients looking to venture into these markets and helps them to advise strategies while going for an investment in these markets. This report will help Investment Bankers, Research Analyst, Management Consultants, Researchers, Wealth Managers etc. to have access to the latest trends and recent developments in medical tourism industry.

Research Highlights

• India offers the cheapest medical treatment in comparison to other Asian medical destination.
• India is forecasted to treat the second highest number of medical tourist in 2013 after Thailand.
• Introduction of cosmetic surgery tax in 2009 by Indian government puts India on the disadvantages position compared to other Asian countries.
• In 2007 more than 70 percent of medical tourists visiting Malaysia were of Indonesian origin.
• Medical tourist arrival in Singapore was 15 percent less in 2007 compared to 2006.
• Thailand is forecasted to have the highest number of medical tourist among other Asian countries by 2013.
• By 2011, South Korea is planning to develop an island for medical tourism with an investment of US$ 315 Million having all types of healthcare facilities. The island is only a two-hour flight from five major cities Seoul, Beijing, Shanghai, Hong Kong and Tokyo.
• South Korea has opened one-stop service center for medical travelers like establishing of information booths and medical information website in five languages.
• South Korea government has allowed foreign investors (individual and institutional) to operate hospitals in the country’s free economic zones (FEZs).

Key Players

This section provides the overview and key financials of prominent players in the Asian medical tourism markets, such as Apollo, Bumrungrad, Raffles and Parkway Health.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.

Table of Contents:

1. Executive Summary
2. Why Medical Tourism is Growing?
2.1 The Role of Cost and Quality
2.2 Proactive role of Asian Governments
2.3 The Internet and the International Patient
2.4 Link between Insurance firms & Employers
2.5 Accreditations
2.5.1 Joint Commission International (JCI)
2.5.2 Trent Accreditation Scheme (TAS)
2.5.3 International Organization for Standardization (ISO)
2.5.4 Regional Accreditation Organizations
3. Asia - Medical Tourism
3.1 Past & Present Scenario
3.1.1 Medical Tourist Arrivals
3.1.2 Medical Tourism Market
3.2 Future Forecast
3.2.1 Medical Tourist Arrivals
3.2.2 Medical Tourism Market
3.3 Clinical Market Segmentation
3.3.1 Cardiac/Heart Surgery
3.3.2 Orthopedic Surgery
3.3.3 Neurological & Spinal Surgery
3.3.4 Dental Tourism
3.3.5 Cosmetic/Plastic Surgery
4. Geographical Distribution
4.1 India
4.1.1 Medical Tourist Arrivals
4.1.2 Medical Tourism Market
4.1.3 Market Drivers
4.1.3.1 Large English Speaking Population
4.1.3.2 Cheapest of all Medical Tourist Destinations
4.1.3.3 Commonwealth Games to generate Billions for India Medical Tourism
4.1.4 Roadblocks
4.1.4.1 New Cosmetic Surgery Tax in India to hit Medical Tourism hard
4.2 Malaysia
4.2.1 Medical Tourist Arrivals
4.2.2 Medical Tourism Market
4.2.3 Market Drivers
4.2.3.1 State of the Art Healthcare Facilities at Competitive Price
4.2.3.2 Affordable and Easy Accommodation
4.2.3.3 Tourism - The Best Part of Medical Tourism in Malaysia
4.2.4 Roadblocks
4.2.4.1 Epidemic Fears
4.2.4.2 Economic Slowdown
4.3 Philippines
4.3.1 Medical Tourist Arrivals
4.3.2 Medical Tourism Market
4.3.3 Market Drivers
4.3.3.1 Low Cost & English Speaking Population
4.3.3.2 Strong Government Support
4.3.4 Roadblocks
4.3.4.1 Lack of Accredited Hospital and Stringent Regulations
4.3.4.2 Long Distances from North America & Europe
4.4 Thailand
4.4.1 Medical Tourist Arrivals
4.4.2 Medical Tourism Market
4.4.3 Market Drivers
4.4.3.1 Biggest Asian Medical Tourist Destination
4.4.3.2 Among Biggest Spa Destinations in World
4.4.4 Roadblocks
4.4.4.1 Politically Unstable State
4.5 Singapore
4.5.1 Medical Tourist Arrivals
4.5.2 Medical Tourism Market
4.5.3 Market Drivers
4.5.3.1 Strong Reputation & No Language Barrier
4.5.3.2 Strong Government Support & Stringent Healthcare Laws
4.5.4 Roadblocks
4.5.4.1 Higher Charges than other Asian Countries
4.6 South Korea
4.6.1 Medical Tourist Arrivals
4.6.2 Medical Tourism Market
4.6.3 Market Drivers
4.6.3.1 Island to be turned into Resort-Style Medical Tourism Centre
4.6.3.2 Providing One-stop Service for Medical Tourism
4.6.3.3 Relaxed Foreign Ownership to boost Medical Travel Industry
4.6.4 Roadblocks
4.6.4.1 Language & Cultural Barriers
5. Key Players
5.1 Apollo Hospitals Enterprise Ltd.
5.2 Bumrungrad Hospital Public Co. Ltd.
5.3 Raffles Medical Group
5.4 Parkway Holdings Ltd.

List of Figures:

2 1: Asia - Cost of Various Surgeries (Heart Bypass, Heart Valve Replacement, Angioplasty, Hip Replacement, Hysterectomy & Knee Replacement) in US, India, Thailand & Singapore (in US$)
3 1: Asia - Cost of Various Surgeries (Heart Bypass, Heart Valve Replacement & Angioplasty) in US, India, Thailand, Singapore & South Korea (in US$)
3 2: Asia – Cost of Artery Bypass Surgery in UK & India (in Pound)
3 3: Asia - Cost of Various Surgeries (Total Hip Replacement & Knee Replacement) in US, UK, India, Thailand, Singapore & South Korea (in US$)
3 4: Asia - Cost of Neurological & Spinal Surgery in UK & India (in US$)
3 5: India - Cost of Dental Treatments in US & India (in US$)
3 6: Asia – Cost of Cosmetic Surgery in US, Canada, India, Thailand & South Korea
4 1: Singapore – Healthcare Facilities (in number), 2005 – 2007
4 2: Singapore – Medical Procedure Costs in Comparison to Other Countries (US, India, Thailand & Costa Rica

List of Charts

3 1: Asia – Medical Tourist Arrivals (in Numbers), 2005 – 2008
3 2: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Medical Tourist Arrivals (in Percent), 2005 – 2008
3 3: Asia – Medical Tourism Market (in Million US$), 2006 – 2008
3 4: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Medical Tourism Market (in Percent), 2006 – 2008
3 5: Asia – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
3 6: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Forecast for Medical Tourist Arrivals (in Percent), 2009 – 2013
3 7: Asia – Forecast for Medical Tourism Market (in Million US$), 2009 – 2013
3 8: Asia (Malaysia, South Korea, Singapore, Thailand, Philippines and India) – Forecast for Medical Tourism Market (in Percent), 2009 – 2013
4 1: India – Medical Tourist Arrivals (in Numbers), 2002 – 2008
4 2: India – Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 3: India – Medical Tourism Market (Million US$), 2002 – 2008
4 4: India – Medical Tourism Market (Million US$), 2009 – 2013
4 5: Malaysia – Medical Tourist Arrivals (in Numbers), 2003 – 2008
4 6: Malaysia – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 7: Malaysia – Medical Tourism Market (Million MYR), 2003 – 2008
4 8: Malaysia – Forecast for Medical Tourism Market (Million MYR), 2009 – 2013
4 9: Malaysia – Country wise Medical Tourist Arrivals (in Percent), 2007
4 10: Philippines – Medical Tourist Arrivals (in Numbers), 2007 – 2008
4 11: Philippines – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2013
4 12: Philippines – Medical Tourism Market (Million US$), 2007 – 2008E
4 13: Philippines – Forecast for Medical Tourism Market (Million US$), 2003 – 2008
4 14: Thailand – Medical Tourist Arrivals (in Million), 2005 – 2008E
4 15: Thailand – Forecast for Medical Tourist Arrivals (in Million), 2009 – 2013
4 16: Thailand – Medical Tourism Market (Billion Baht), 2005 – 2008E
4 17: Thailand – Forecast for Medical Tourism Market (Billion Baht), 2009 – 2013
4 18: Singapore – Medical Tourist Arrivals (in Thousands), 2004 – 2008E
4 19: Singapore – Forecast for Medical Tourist Arrivals (in Thousands), 2009 – 2013
4 20: Singapore – Medical Tourism Market (Million US$), 2004 – 2008E
4 21: Singapore – Forecast for Medical Tourism Market (Million US$), 2009 – 2013
4 22: South Korea – Medical Tourist Arrivals (in Numbers), 2005, 2007 – 2008
4 23: South Korea – Forecast for Medical Tourist Arrivals (in Numbers), 2009 – 2015
4 24: South Korea – Medical Tourism Market (Million US$), 2006 – 2008E
4 25: South Korea – Forecast for Medical Tourism Market (Million US$), 2009 – 2015
4 26: South Korea – Government & Private Sector Investment in Healthcare Town of Jeju Free International City Development Center (in Million US$ & Percent)

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Asia-Medical-Tourism-Analysis.html

Medical Nanotechnology Markets

Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare. According to U.S. National Science Foundation estimates, by 2015 the annual global market for nano-related goods and services will top $1 trillion, thus making it one of the fastest-growing industries in history. Assuming that these figures prove to be accurate, nanotechnology will emerge as a larger economic force than the combined telecommunications and information technology industries at the beginning of the technology boom of the late 1990s.

This TriMark Publications report covers the specific segments of the medical nanotechnology markets, with particular emphasis on those segments where this emerging technology is or shows the potential to be most impactful. Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery and medical technologies. The discipline has already yielded healthcare discoveries that have been used for drug delivery and diagnostic purposes. In this study, we describe various nanotechnologies under development for biological and medical purposes and assess their potential. Moreover, this analysis is arranged to provide an overview of the regulatory issues faced by the medical nanotechnology industry and focuses on how specific segments within the industry are poised for high future growth.

Table of Contents:

1 Overview 6
1.1 Statement of Report 6
1.2 About This Report 6
1.3 Scope of the Report 8
1.4 Methodology 8
1.5 Executive Summary 10

2 Medical Products (Drugs, Devices and Nutraceuticals) Nanotechnology Markets 13
2.1 Background 13
2.2 Market Calculations 13
2.3 Market Demands 14
2.4 Market Overview 18
2.4.1 The Role of Nanotechnologies in Medicine 18
2.4.2 Nanotechnology Sector Challenges 21
2.4.3 Nanotechnology Sector Drivers 21
2.4.4 Nanotechnology Sector Restraints 21
2.5 Nanotechnology Medical Product Market Segments 21
2.5.1 Overview 21
2.5.2 World Markets 22
2.5.3 U.S. Market 24
2.5.4 European Market 25
2.5.5 Japanese Market 26
2.5.6 Asian Market 27
2.5.7 Middle East 29
2.5.8 ROW 30

3 Medical and Life Science Nanotechnology Markets 32
3.1 Nano-Particles 33
3.2 Market for Nano-Particles in Life Sciences and Medicine 34
3.2.1 Key Players 34
3.2.2 Application Manufacturers 36
3.3 Dendrimers 36
3.3.1 PAMAM Dendrimers 36
3.3.2 Market for Nanocapsules in Life Sciences and Healthcare 37
3.3.3 Key Players 37
3.4 Market for Nanoporous and Nanostructured Materials in Life Sciences and Healthcare 37
3.4.1 Key Players 37
3.4.2 Nanofiltration 38
3.5 Nanodevices, Nanosensors and Quantum Dots 38
3.5.1 Sector Overview 38
3.5.2 Market for Quantum Dots in Life Sciences and Medicine 39
3.5.3 Commercial Applications for Quantum Dots 39
3.5.4 Key Players 40
3.5.5 Nanomaterials Suppliers 41
3.5.6 Application Manufacturers 41
3.6 Nanocoatings 42
3.7 Nanocomposites 42
3.8 Nanoarrays 42
3.8.1 Bead NanoArrays: A High-Sensitivity Detection System 43
3.9 Fullerenes 43
3.9.1 Key Applications and Market Opportunities 44
3.9.2 Medical Market Uses for Carbon Nanotubes 44
3.9.3 Key Players, Including Application Manufacturers, End Users and Nanomaterials Suppliers 45
3.10 Liposome-like Nano-Particles 45
3.10.1 Nanostructured Lipid Carriers 46
3.10.2 DauxoXome® Liposomal Formulation 46
3.11 Nanosensors 46
3.11.1 Microcantilever Sensors and Photonic Sensors 46
3.11.2 Field-Effect Nanoplate Devices 46
3.11.3 Electrochemical-Transducing Electrode Systems 47

4 Technology Issues 48
4.1 Nanotechnology in Drug Delivery and Development 48
4.1.1 Drug Delivery Using Nanotechnology 50
4.1.2 Design of Nanotechnology-Based Drug Delivery Systems 52
4.1.3 Using Magnetic Nano-Particles in Targeted Drug Delivery 53
4.1.4 Cancer Drug Delivery 53
4.1.5 Nano-Particle-Mediated Delivery of siRNA 55
4.1.6 Targeting Angiogenesis with Nano-Particles 55
4.1.7 Nanosystems and Inflammation 56
4.1.8 The Chiral Drug Development Process 56
4.1.9 Reasons Why the Drug Delivery Market is Rapidly Expanding 57
4.2 Categories of Medical Nanotechnology Products 57
4.2.1 Surgical Steel Devices 58
4.2.2 Contrast-Enhancing Agents for MRI (Magnetic Resonance Imaging) 58
4.2.3 Wound Dressings / Anti-Microbial Textiles 59
4.2.4 Nanocoated Surgical Blades 59
4.2.5 Suture Needles and Microneedles 59
4.2.6 Catheters for Minimally-Invasive Surgery 59
4.2.7 Optical Nanosurgery 59
4.2.8 Nanocoated or Nanocontoured Implant Surfaces 60
4.3 Biosensors and Biodetection 60
4.3.1 Cantilever Arrays 60
4.3.2 Nanosensors 60
4.3.3 Optical Sensors 60
4.3.4 Nano-Particle Sensors and Detectors 61
4.3.5 In Vitro Diagnostics 61
4.3.6 Imaging, In Vivo Diagnosis and Theranostics 64
4.4 Vaccines-Virus-Like Particles (VLPs) 65
4.5 Transdermal Drug Delivery 65
4.6 Phage Microarrays 65
4.7 Neuroscience 66
4.8 Nanotechnology Materials for Medical Products 67
4.8.1 Dental Materials 67
4.8.2 Bone Replacement 68
4.8.3 Contact Lenses 68
4.9 New Drug Development 68
4.10 Future Directions 69
4.10.1 Sources of Nano Development 69
4.10.2 Commercialization 70
4.10.3 Current/Pending Clinical Trials on New Products and Emerging Technologies 70
4.10.4 Future Directions 72
4.11 Key Technology Findings for Medical Uses of Nanotechnology 72

5 Business Trends 74
5.1 Market Forces 74
5.1.1 Market Drivers 74
5.1.2 Market Restraints 74
5.1.3 Medical / Clinical Studies 74
5.1.4 Demographics 75
5.2 Market Prospects 75
5.3 Marketing and Distribution 75
5.4 Competitive Landscape 76
5.5 Business Developments 76
5.5.1 Drug Pedigrees 76
5.6 Acquisitions and Partnerships 77
5.7 Key Players 77
5.8 Patent Climate 77
5.9 Investment Climate 78
5.9.1 U.S. Government 79
5.9.2 Europe 80
5.10 Venture Capital Environment 80
5.10.1 Medical and Health Nanotech Venture Companies 81
5.10.2 Pharma and Biotech Nanotech Venture Companies 83
5.11 Business Strategies for Medical Nanotechnology 88
5.12 Nanotechnology Questions 90
5.12.1 What Are the Near-Term Business Opportunities in the Medical Nanotechnology Markets? 90
5.12.2 What Are the Business Models Currently Used by Companies in the Medical Nanotechnology Markets? 90
5.12.3 How Will Manufacturers, Researchers, Physicians, Patients and Payers Influence the Medical Nanotechnology Markets? 91
5.12.4 What Are the Drivers and Bottlenecks Influencing the Medical Nanotechnology Markets? 91
5.12.5 What Are the Current and Emerging Technologies used in the Medical Nanotechnology Markets? 91
5.12.6 Who Holds the Proprietary Rights to the Medical Nanotechnology Markets, Especially in such a Multidisciplinary Environment? 92
5.12.7 What Are Current Applications of These Technologies? 92
5.12.8 What Regulatory Processes Must Medical Nanotechnology Undergo in the U.S., Japan and Europe? 92
5.12.9 How Will New or Emerging Medical Nanotechnologies Change Treatment and Payment Paradigms? 92
5.12.10 How Will Medical Nanotechnologies Reduce Adverse Clinical Reactions and Decrease Total Patient Care Cost? 93
5.12.11 How Will Medical Nanotechnology Reduce Healthcare Expenditures? 93
5.12.12 How Will Medical Nanotechnology Decrease Patient Diagnostic Testing Costs? 93
5.12.13 What is the Role of Nanotechnology in Drug Development? 93
5.12.14 Which Medical Nanotechnology Product Categories Are Driving Growth? 94
5.12.15 How Are Biomarkers Being Developed Using Nanotechnology? 94
5.12.16 What Companies Are Developing Nanotechnology Drug Delivery Systems? 94
5.12.17 How Are Nano-Optical Tagging Technologies Used in Animal Drug Safety Assessment Studies? 94
5.12.18 What Nanotechnology Platforms Are Being Used in Point of Care Diagnostic Testing? 95

6 Technology Assessment 96
6.1 Current Technologies for Nano 96
6.1.1 Nanodiagnostics 96
6.1.2 Competitive Analysis of Nano-Particle Assays 99
6.1.3 In Vivo Imaging 99
6.1.4 In Vitro Clinical Diagnostics 99
6.2 Future Technologies 101
6.3 Technology Accelerators, Roadblocks and Challenges 103
6.3.1 Technology Accelerators 103
6.3.2 Technology Roadblocks and Challenges 103
6.3.3 Public Awareness 104
6.4 Nanotechnology Product Trends and New Concepts for Medical Applications 106
6.4.1 Market Trends-Diagnostics 106
6.4.2 Market Trends-Therapies 115
6.4.3 Market Trends-Preventive and Other 120
6.4.4 Nanofibers in Medical Applications 124
6.4.5 Dental Applications 125
6.4.6 Optical Applications 126
6.5 Production Methods 126

7 Medical Nanotechnology Market Regulation and Reimbursement 128
7.1 Market Segments 128
7.1.1 Diagnostics 128
7.1.2 Therapies 128
7.1.3 Preventive 128
7.2 Customer Needs 128
7.3 Competitor Analysis 128
7.4 Pricing Pressures 129
7.5 U.S. Medicare and Other Government Agency Issues 129
7.6 Third-Party Reimbursement 129
7.7 Regulatory Trends 129
7.7.1 Regulatory Policy for Nanotechnology Drugs and Medical Devices 130
7.7.2 Current Good Manufacturing Practices (cGMPs) 133
7.7.3 Current Progress 134
7.7.4 Future Regulatory Trends 134
7.7.5 Key Issues 136
7.7.6 Labeling Requirements 136
7.8 Government Initiatives 136
7.8.1 NNI Research Centers 137
7.8.2 NNI Centers and Networks of Excellence 137
7.8.3 FDA’s Nanotechnology Task Force 137
7.8.4 Dutch Government Nano Action Plan 138
7.8.5 Other Research Centers 138
7.9 Medical Regulatory and cGMPs Issues 139
7.10 New Technology Concerns 140
7.11 Use Environment 141
7.11.1 Cancer 141
7.11.2 Medical Review 141
7.12 Risk Assessment 141
7.12.1 Risk Management (ISO 14971:2007) 141
7.12.2 Toxicology Assessment 141
7.12.3 Safety Evaluation 142
7.13 Cautions for Medical Nanotechnology Platforms 144
7.13.1 ETUC Precautionary Principle Applied to Nanotechnologies 145
7.13.2 Possible Risks to Human Health from Nanotechnology Products 145

8 Corporate Profiles 146
8.1 Abbott Laboratories 146
8.2 Abraxis Biosciences 146
8.2.1 NDA Pipeline 147
8.3 Aduro BioTech 148
8.4 Advanced Magnetics (AMAG Pharmaceuticals) 148
8.5 Alnis BioSciences 149
8.6 APP Pharmaceuticals 149
8.7 Arrowhead Research Corporation 150
8.8 Baxter International 151
8.9 Bristol-Myers Squibb 151
8.10 Caliper 151
8.11 Capsulution NanoScience AG 152
8.12 CytRx Corporation 152
8.13 Dendritech, Inc. 152
8.14 Dendritic Nanotechnologies, Inc. 152
8.15 Dow Chemical 153
8.16 DuPont 153
8.16.1 The Framework 155
8.17 Elan Drug Delivery (see also Bristol-Myers Squibb) 156
8.18 Evident Technologies 157
8.19 Evolved Nanomaterial Sciences (ENS) 157
8.20 Flamel Technologies 157
8.21 General Electric 160
8.22 GlaxoSmithKline 160
8.23 Honeywell International 160
8.24 Invitrogen 161
8.25 Nano-C 162
8.26 Nanocyl SA 163
8.27 Nanogen, Inc. 163
8.28 Nanolab Systems 164
8.29 NanoPass Technologies, Ltd. 164
8.30 Nanophase Technologies Corporation 164
8.31 Nanospectra Biosciences 165
8.32 Nanosphere, Inc. 165
8.33 Nanosys 166
8.34 New England Precision Grinding (NEPG) 166
8.35 Novartis 167
8.36 Novavax 167
8.37 Nucryst (Westaim) Pharmaceuticals 168
8.38 Orthovita 168
8.39 Phillips 168
8.40 pSivida Corporation 169
8.41 Quantum Dot Corporation 169
8.42 Roche 170
8.43 Sandvik Bioline 170
8.44 Starpharma Holdings, Limited 171
8.45 Sigma Aldrich 172
8.46 Wyeth Pharmaceuticals 173

9 Appendix: Nanotechnology References 174

10 Appendix: Glossary of Terms in Nanotechnology 175
10.1 Bionanotechnology 175
10.1.1 Nanopore Sequencing 175
10.1.2 Cantilevers with Functionalized Tips 175
10.1.3 Microneedles 175
10.1.4 Microchips for Drug Delivery 175
10.1.5 Nucleic Acid Lattices and Scaffolds 176
10.1.6 Nanofibers as Biomaterials 176
10.1.7 Carbon Nanotubes 177
10.2 Definition of Nano-Particles with Biological and Medical Applications 177
10.2.1 Superparamagnetic Iron Oxide Crystals 177
10.2.2 Quantum Dots 178
10.2.3 Dendrimers 178
10.2.4 Polymeric Micelles 178
10.2.5 Liposomes 178
10.2.6 Nanospheres 179
10.2.7 Aquasomes (Carbohydrate-Ceramic Nano-Particles) 179
10.2.8 Polyplexes/Lipopolyplexes 179

11 Appendix: NNI Centers and Networks of Excellence 180
11.1 National Science Foundation 180
11.2 Department of Energy 181
11.3 Department of Defense 181
11.4 National Aeronautics and Space Administration (NASA) 182
11.5 National Institute for Occupational Safety and Health 182
11.6 National Institute of Standards and Technology 182
11.7 National Institutes of Health 182

List of Figure :

Figure 2.1: End-User Markets for Nanotechnology, 2007 15
Figure 2.2: Nanometer Scale 18
Figure 2.3: International Per Capita Healthcare Spending by Country, 2006 22
Figure 2.4: World Nanomedical Market Shares, 2007 23
Figure 2.5: Total Spending on Healthcare in the U.S., 1960 to 2007 24
Figure 3.1: Nanotechnology Applications 33
Figure 3.2: Carbon Nanotubes 44
Figure 4.1: Depiction of nab Technology 49
Figure 7.1: FDA Product Validation Chart 133
Figure 7.2: FDA Product Lifecycle Model 135
Figure 8.1: Sigma Aldrich Sales Distribution 172

List of Table :

Table 2.1: Global Market for Nanotechnology Products, 2005 to 2013 15
Table 2.2: Nanotechnology Materials for Consumer Products, 2005 to 2013 16
Table 2.3: Nanotechnology Markets Worldwide by Industry, 2002 to 2015 16
Table 2.4: Nanotechnology Development Worldwide by Region, 2002 to 2015 16
Table 2.5: Currently-Growing Nanofabrication Techniques 18
Table 2.6: Global Nanomedicine Market, 2004 to 2013 22
Table 2.7: Nanomedicine Market Revenues by Product Segment, 2007 23
Table 2.8: Global Nanomedicine Market by Geographic Segment, 2004 to 2013 23
Table 2.9: U.S. Nanomedicine Market, 2004 to 2013 24
Table 2.10: European Nanomedicine Market, 2004 to 2013 25
Table 2.11: Japanese Nanomedicine Market, 2004 to 2013 26
Table 2.12: Japanese Nanotechnology Product Market Forecast 27
Table 2.13: Government Funding for Nanotechnology Research and Development, 1997 to 2008 30
Table 2.14: Global Nanotechnology R&D Spending, 1997 to 2013 30
Table 2.15: Global Growth in Nanotechnology R&D, 1997 to 2013 31
Table 3.1: Global Market for Nanotechnology Applications in the Life Sciences, 2005 to 2012 32
Table 3.2: Market for Nano-Particles in Life Sciences and Medicine, 2004 to 2012 34
Table 3.2: Market for Nanostructured Materials in Life Sciences and Medicine, 2004 to 2012 37
Table 3.4: Market for Nanodevices in Life Sciences and Medicine, 2004 to 2012 39
Table 3.5: Commercial Applications of Quantum Dots 40
Table 3.6: Market for Nanocomposites in Life Sciences and Medicine, 2004 to 2012 42
Table 3.7: Liposomal Formulations Used in Nanotechnology 45
Table 3.8: Types of Nanoparticulate Drug Delivery Systems 47
Table 4.1: FDA-Approved Drugs Developed with Nanotechnology-Based Formulations 49
Table 4.2: Key Effectors of Drug Delivery Using Nanomaterials 50
Table 4.3: Nanoscale Applications for Drug Delivery in Pharmaceutical Drug Development 51
Table 4.4: Drug Delivery Nanotechnology Market Drivers Ranked in Order of Impact 51
Table 4.5: Drug Delivery Nanotechnology Market Restraints Ranked in Order of Impact 51
Table 4.6: Anti-Cancer Drugs Formulated Using Nanomaterials 54
Table 4.7: Nanomaterials for in vitro RNAi Delivery 54
Table 4.8: Use of Peptide-Based Nanotubes for Biological Active Targets 55
Table 4.9: Lab-on-Chip and Microfluidic Chip Technology Innovations 62
Table 4.10: Diagnostic Nanotechnology Market Drivers Ranked in Order of Impact 63
Table 4.11: Diagnostic Nanotechnology Market Restraints Ranked in Order of Impact 63
Table 4.12: FDA-Approved In Vivo Imaging Materials Developed with Nanotechnology-Based Formulations 64
Table 4.13: Application Areas for Phage Nanotechnology Platforms 66
Table 4.14: Application Areas for Neuroscience Nanotechnology Platforms 66
Table 4.15: Nanotechnology Application Areas for Medical Nanomaterials 67
Table 4.16: FDA-Approved Dental Biomaterials Developed with Nanotechnology-Based Formulations 68
Table 4.17: Drug Discovery Nanotechnology Market Drivers Ranked in Order of Impact 68
Table 4.18: Drug Discovery Nanotechnology Market Restraints Ranked in Order of Impact 68
Table 4.19: Examples of Proposed U.S. NNI Interagency Collaborative Activities 70
Table 5.1: Medical Nanotechnology Market Drivers-Global, 2008 to 2016 75
Table 5.2: Medical Nanotechnology Market Restraints-Global, 2008 to 2016 75
Table 5.3: U.S. Nanotechnology Patents Issued per Year, 1996 to 2006 78
Table 5.4: Sources of Nanotechnology Funds 79
Table 5.5: National Government Funding Leaders for Nanotechnology, 2007 79
Table 5.6: Total Investments in Venture-Backed Nanotechnology Companies, 1997 to 2008 81
Table 5.7: Leading Nanotechnology Start-Up Companies 81
Table 6.1: Summary of Key Advantages for Nanotechnology 96
Table 6.2: Nanotechnology Platforms Used for Diagnostics and Imaging 96
Table 6.3: FDA-Approved In Vitro Diagnostics Developed with Nanotechnology-Based Formulations 97
Table 6.4: Applications of Veridex Nanotechnology Platform for Diagnostic Assays 98
Table 6.5: Characteristics of Gold Nano-Particle Technology for Diagnostic Testing 100
Table 6.6: Overview of Future Nanomedical Technology Development 101
Table 6.7: Recent Developments in Nanotechnology for Drug Delivery and Drug Discovery 101
Table 6.8: Recent Developments in Nanomaterials and Nanotechnology-Based Devices 102
Table 6.9: Recent Nanotechnology Applications in Diagnostics 102
Table 6.10: Future Nanomedical Technology Platforms 102
Table 6.11: Additional Global Market Trends 127
Table 8.1: AMAG Nanotechnology Products and Candidates 149

For more info please visit
http://www.bharatbook.com/Market-Research-Reports/Medical-Nanotechnology-Markets-.html

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. hESCs are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

hESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

This market report recognizes that a wide range of products and services are needed to support this active and well-funded research community. Thus, this report provides:

* Discussion of key advances in hESC research
* A breakdown of hESC research applications, including shared priorities and priorities by segment
* hESC patent analysis
* Historical and future growth projections for the hESC market
* Competitive analysis of providers of hESC research tools
* Overview of specialty pharma companies developing hESC therapies
* Overview of toxicology testing legislation impacting use of hESC in toxicology applications
* A breakdown of hESC research product categories
* Suggestions for novel NSC research products, including cells, kits, assays, media and reagents
* Guidance for companies that wish to offer hESCs products
* And more…

Table of Contents:

I. Background

A. Human Embryonic Stem Cells (hESC)
B. Brief History
C. Use in Treatment of Disease
D. Human Embryonic Stem Cell Line Availability

II. Available Stem Cell Lines

A. NIH Registry Approved
B. Sources of Additional Published hESC Lines
C. Sources of Additional Unpublished hESC Lines

III. Applications

A. Basic Stem Cell Biology
B. Cellular Therapies

1. Overview
2. Heart Regeneration
3. Pancreatic Islet Cell Replacement
4. Neural Regeneration

C. Tissue Engineering
D. Toxicology Testing

IV. Application Priorities

A. Overall

1. Cell-Based Therapies: Greatest shared priority across research community

a. Beneficial hESC Characteristics
b. hESC Safety Concerns
c. hESC Characterization in Vitro
d. hESC Characterization in Vivo

2. Toxicology Assessment: Another area of huge potential

a. Overview
b. Commercial Interest

B. By Segment

1. Academic
2. Biotech
3. Pharma

V. Patents

A. Key U.S. Neuronal Stem and Progenitor Cell Patents

B. Additional Key U.S. Patents

1. Geron Corporation
2. Regents of the University of California
3. BresaGen Inc.
4. Regeneron Pharmaceuticals, Inc.
5. Vanderbuilt University

C. Additional Key European Patents

1. ES Cell International PTE Ltd.
2. DNAVEC Research Inc.
3. University of Edinburgh

VI. Historical and Future Growth Projections

A. PubMed Analysis

1. Historical Analysis (Trailing 10 Years)
2. Future Growth Predictions (5-Year Forecasts)
3. Breakdown of ESC Research by Species

B. CRISP Analysis
C. Patent Analysis

1. All Fields
2. Abstract Only

VII. hESC PRODUCT COMPETITORS

A. Cellartis AB

1. Human embryonic stem cell lines
2. Monoclonal Antibodies for hESC Research
3. Differentiated Cell Products
4. Associated hESC products

B. Vitrolife

C. Tataa Biocenter

D. Invitrogen

1. hESC Culture Media & Reagents
2. hESC-qualified Basement Membrane Extract
3. hESC cDNA Libraries
4. hESC Reporter Cells
5. hESC PCR Kits
6. hESC Stem Cell Antibodies
7. hESC Stem Cell Growth Factors

E. Stem Cell Technologies

1. hESC Culture Media & Reagents
2. hESC Primary & Secondary Antibodies

F. BD Biosciences

G. Chemicon

1. hESC Culture Media and Reagents
2. hESC Lines
3. hESC Kits
4. hESC Antibodies

H. R&D Systems

I. SA Biosciences

J. Thermo Scientific

K. Australian Stem Cell Centre

VIII. Specialty Pharmaceutical Companies developing hESC Therapies

A. Geron
B. Novocell
C. Cell Cure Neurosciences Ltd
D. Cell Dynamics International
E. Advanced Cell Technology

IX. Featured Labs (Potential Customers)

A. Academic Labs
B. Private Labs
C. Government Labs
D. International Labs

X. Toxicology Testing Legislation

1. European Union to Ban Animal-Testing for Cosmetic Development in 2009

2. Responses to the European Ban on Animal Testing for Cosmetic Development

a. Overview
b. Skin Irritation
c. Eye Irritation
d. Skin Sensitisation
e. Mutagenicity/Genotoxicity
f. Reproductive Toxicity

3. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. Product Development Suggestions

A. Product Categories

1. hESCs
2. hESC Derivative Cells
3. hESC Reporter Cells
4. hESC Antibodies
5. hESC Characterization & PCR Kits
6. hESC Qualified BME
7. hESC cDNA Libraries
8. hESC Growth Factors
9. hESC Media and Culture Reagents

B. Product Ideas & Suggestions

1. Areas of Underdeveloped Competition
2. Mouse ESC Products
3. iPS Cells Products
4. Non-animal-derived Culture Reagents for hESCs
5. Strategic Collaborations
6. Products for generating Pure ESC populations
7. hESC Toxicity Assay Kit

XII. Events of Interest

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Opportunities-in-Human-Embryonic-Stem-Cells-hESCs.html

According to “Ukraine Pharma - New Opportunities for Growth”, a new research report, Ukraine promises to be one of the most lucrative pharmaceutical markets in the world. In 2007, the Ukrainian pharmaceutical market grew by nearly 21% to register revenues in excess of US$ 2 Billion. The market is characterized by an increasing proportion of imported and high-priced drugs. In 2007, the average unit price of drugs sold in Ukraine increased by nearly 20%, strongly pushing the value of pharmaceutical sales, despite a relatively ordinary growth in sales volume.

The future outlook of the industry also seems very positive as the market is expected to be driven by a number of reforms recently proposed by the government. Factors such as increasing penetration of health insurance and increasing disposable incomes of consumers will also fuel growth. The lack of effective price controls and high margins are also expected to lure foreign players in this market. The country’s unstable political environment, however, will be the biggest hurdle for investments. But overall, the market is expected to grow strongly, exceeding US$ 4.5 Billion in revenues by 2012.

This report gives an extensive and objective analysis on the pharmaceutical market of Ukraine. It investigates both the past and present trends in the market, with its main focus on the future trends shaping the industry. The study discusses the performance of both the retail and hospital segments of the pharmaceutical market in detail and based on various present and future indicators, analyzes the future of these segments. This report gives valuable information to manufacturers/investors planning to enter the Ukrainian pharmaceutical market.

The Report Provides Forecasts on

*Macroeconomic Indicators
*Healthcare Indicators
*Population & Demographics
*Disease Profiles
*Total Pharmaceutical Market
*Retail Pharmaceutical Market
*Hospital Pharmaceutical Market

Key Player Profiling

Ukraine Pharma - New Opportunities for Growth” provides brief profiling on key players, both domestic and foreign, currently operating in the Ukraine pharmaceutical market. This section describes the revenues and growth of players in the total pharmaceutical market, retail market and hospital market. Performance of key drugs in various segments of the market has also been evaluated. Business profiles of top five players, Berlin Chemie, Sanofi Aventis, Novartis, Arterium and Darnitsa, have also been discussed in this report.

Table of Contents:

1. Analyst View
2. What Makes Ukraine so Lucrative
2.1 Robust Economic Growth
2.2 Improved Investment Climate
2.3 Growth of High-priced Drugs
2.4 Healthcare Infrastructure
3. Population & Demographics
4. The Pharmaceutical Market
4.1 Market Size
4.2 Imported & Domestically Manufactured Drugs
4.3 Leading Domestic & Foreign Manufacturers
4.4 Leading Pharmaceutical Distributors
5. The Retail Market
5.1 Market Size
5.2 Prescription & OTC Sales
5.3 Therapeutic Segmentation
5.4 Leading Domestic & Foreign Players
5.5 Leading Drugs
5.6 Price Characteristics of Drug Consumption
6. The Hospital Market
6.1 Market Size
6.2 Prescription & OTC Sales
6.3 Therapeutic Segmentation
6.4 Leading Domestic & Foreign Players
6.5 Leading Drugs
6.6 Price Characteristics of Drug Consumption
7. Opportunities
7.1 Clinical Trials Market
7.2 Contract Manufacturing
7.3 Medical Devices Market
8. Roadblocks
8.1 Unstable Political Environment
8.2 Declining Population
8.3 Lack of Effective Reimbursement System
8.4 Opaque Tax System
9. Forecasts
9.1 Critical Success & Risk Factors Shaping the Future
9.1.1 Critical Success Factors
9.1.2 Critical Risk Factors
9.2 Pharmaceutical Market
9.2.1 Retail Market
9.2.2 Hospital Market
10. Key Company Profiles
10.1 Berlin-Chemie
10.2 Sanofi-Aventis Group
10.3 Novartis
10.4 Arterium
10.5 Darnitsa Pharma

List of Figures:
Figure 2-1: Ukraine - Nominal GDP (in Billion US$), 2001-2007 & 2012F
Figure 2-2: Ukraine - Disposable Income per Head (in US$), 2001-2007E & 2012F
Figure 2-3: Ukraine - Healthcare Expenditure per Head (in US$), 2001-2007E & 2012F
Figure 2-4: Ukraine - Hospital Beds (per ‘000 Population), 2001-2007E & 2012F
Figure 2-5: Ukraine - Doctors (per ‘000 Population), 2002-2007E & 2012F
Figure 3-1: Ukraine - Population (in Million), 2001-2007E & 2012F
Figure 3-2: Ukraine - Population Breakup by Age Group (%), 2005-2007E & 2012F
Figure 3-3: Ukraine - Leading Causes of Death (%), 2005
Figure 3-4: Ukraine - Deaths due to Leading Causes (in Number), 2005
Figure 3-5: Ukraine - Forecast for Leading Causes of Death (%), 2030
Figure 3-6: US - Forecast for Deaths due to Leading Causes (in Number), 2030
Figure 4-1: Ukraine - Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 4-2: Ukraine - Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 4-3: Ukraine - Proportion of Generic & Branded Drugs (%)
Figure 4-4: Ukraine - Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Value (%), 2006 & 2007
Figure 4-5: Ukraine - Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Volume (%), 2006 & 2007
Figure 4-6: Ukarine - Pharmaceutical Imports (in Billion US$), 2005-2007E
Figure 4-7: Ukarine - Share of Imported & Domestically Manufactured Drugs in Pharmaceutical Market by Sales Value (%), 2006 & 2007E
Figure 4-8: Ukarine - Top 5 Pharmaceutical Importing Countries (in ‘000 Units) 2006 & 2007
Figure 5-1: Ukraine - Retail Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 5-2: Ukraine - Retail Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 5-3: Ukraine - Share of RX & OTC Drugs in Retail Pharmaceutical Market by Sales Value (%), 2006 & 2007
Figure 5-4: Ukraine - Share of RX & OTC Drugs in Retail Pharmaceutical Market by Sales Volume (%), 2006 & 2007
Figure 5-5: Ukraine - Retail Pharmaceutical Market by Therapeutic Area (%), 2007
Figure 6-1: Ukraine - Hospital Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 6-2: Ukraine - Hospital Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 6-3: Ukraine - Share of RX & OTC Drugs in Hospital Pharmaceutical Market by Sales Value (%), Q1-Q3 2007
Figure 6-4: Ukraine - Share of RX & OTC Drugs in Hospital Pharmaceutical Market by Sales Volume (%), Q1-Q3 2007
Figure 6-5: Ukraine - Hospital Pharmaceutical-Market by Therapeutic Area (%), Q1-Q3 2007
Figure 7-1: Ukraine - Medical Devices Market (in Million US$), 2007E & 2012F
Figure 9-1: Ukraine - Forecast for Pharmaceutical Market (in Million US$), 2008-2012
Figure 9-2: Ukraine - Forecast for Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Value (%), 2008-2012
Figure 9-3: Ukraine - Forecast for Retail Pharmaceutical Market (in Million US$), 2008-2012
Figure 9-4: Ukraine - Forecast for Hospital Pharmaceutical Market (in Million US$), 2008-2012

List of Tables:
Table 2-1: Ukraine - Average Price per Trading Unit of Pharmaceuticals (in US$), 2006 & 2007
Table 2-2: Ukraine - Hospital Beds & Doctors w.r.t. Developed Countries (per ‘000 Population), 2007E
Table 4-1: Ukraine - Statistics of Top Players in Pharmaceutical Market (2007)
Table 4-2: Ukraine - Market Share of Top Pharmaceutical Distributors (%), 2006 & 2007
Table 5-1: Ukraine - Statistics of Top Players in Retail Pharmaceutical Market (2007)
Table 5-2: Ukraine - Statistics of Top 10 Drugs in Retail Pharmaceutical Market (2007)
Table 5-3: Ukraine - Price Characteristics of Drug Consumption in Retail Pharmaceutical Market
Table 6-1: Ukraine - Statistics of Top Players in Hospital Pharmaceutical Market (2007)
Table 6-2: Ukraine - Statistics of Top 20 Drugs in Hospital Pharmaceutical Market (Q1-Q3 2007)
Table 6-3: Ukraine - Average Retail Price per Drug in Hospital Pharmaceutical Market (in US$), Q1-Q3 2006 & Q1-Q3 2007
Table 9-1: Ukraine - Critical Sucess Factors for Pharmaceutical Market
Table 9-2: Ukraine - Critical Risk Factors for Pharmaceutical Market

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Ukraine-Pharma-New-Opportunities-for-Growth.html

Canadian Pharmacy Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

The Canadian pharmaceutical market is one of the fastest growing markets in the world, however strong generic erosion is expected over the next five years due to upcoming patent expiries for leading products. Although the product pipeline currently lacks the potential to offset these sales losses, the TRIPS compliant 20-year patent period and recent amendments to the Patented Medicines Regulations are expected to drive the revenues of branded drugs. ‘The Canadian Pharmaceutical Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage of the Canadian pharma market, including a detailed analysis of regulatory, pricing and reimbursement frameworks that govern the country’s policy environment. The structure of the market is examined with a breakdown of pharma distribution networks, licensing trends and sales by province/territory. Sales trends amongst leading brands, therapy areas and companies are also identified. This report evaluates the competitive landscape of the region, with an analysis of the portfolios and pipelines of leading branded, generics and biotechnology companies. The potential of key pipeline compounds is also assessed, and revenue/epidemiological forecasts are provided for the period 2009-13.

Table of Contents

The Canadian Pharmaceutical Market Outlook to 2013

Executive Summary 10

Overview of Canada 10

Pharmaceutical regulation, pricing and reimbursement 11

Pharmaceutical market structure 12

Pipeline analysis 13

Chapter 1 Scope and methodology 16

Scope 16

Methodology 16

Chapter 2 Overview of Canada 18

Summary 18

Introduction 18

The Canadian economy enters recession 20

An aging Canada 21

Disease burden in Canada – forecast to 2013 23

Arthritis 24

Asthma 24

Chronic obstructive pulmonary disease (COPD) 24

Diabetes 24

Hypertension and heart diseases 25

HIV/AIDS 25

Parkinson’s and Alzheimer’s disease 25

Cancer 25

Chapter 3 Pharmaceutical regulation,

pricing and reimbursement 28

Summary 28

Introduction 29

Pharmaceutical Regulation 30

Intellectual property rights 31

Clinical trial regulation 32

Regulatory submissions and review times 34

Marketing authorization 36

Adverse drug reaction monitoring 37

Pharmaceutical pricing 37

Pricing control policies – an industry perspective 39

Drug coverage and reimbursement 40

Formulary listing 41

Reimbursement 42

Catastrophic drug coverage plan 43

Key trends in regulation, pricing and reimbursement 43

Drug majors unperturbed by the DTCA ban 43

CanWest Mediaworks’ legal suit over the DTCA 44

Higher generic drug prices cause concern of rising drug expenditure 44

Introduction of Quebec’s maximum price payable policy 45

Compulsory formulary listing leads to irrational pricing in Quebec 45

BC Pharmacare price referencing system unfriendly to branded drugs 45

Pharmaceutical task force offers hope for drug makers in BC 46

Increased co-insurance and deductibles on pharmaceutical consumption 46

COMPUS is likely to usher in a generic prescription era 46

Chapter 4 Pharmaceutical market structure 48

Summary 48

Introduction 49

Pharmaceutical distribution 49

Independent pharmacy distributors (IPD) 49

Self-distributors 50

Retail and hospital pharmacies 50

Independent pharmacies 50

Pharmacy groups 51

Hospital pharmacies 51

Pharmaceutical sales and market analysis 52

Drug sales by province and territory 52

Licensing trends 53

Market analysis by therapeutic area 54

Market analysis by drug classes 56

Market analysis by leading brands 57

Market analysis by key players 58

Branded drug manufacturers 60

Pfizer Canada 60

Sales analysis by therapeutic area 61

Sales analysis of leading brands 62

J&J Canada 63

Sales analysis by therapeutic area 64

Sales analysis of leading brands 66

AstraZeneca Canada 67

Sales analysis by therapeutic area 68

Sales analysis of leading brands 69

GSK Canada 70

Sales analysis by therapeutic area 71

Sales analysis of leading brands 72

Novartis Canada 73

Sales analysis by therapeutic area 74

Sales analysis of leading brands 75

Generic drug manufacturers 76

Apotex Canada 77

Sales analysis by therapeutic area 78

Sales analysis of leading brands 79

Novopharm 80

Sales analysis by therapeutic area 81

Sales analysis of leading brands 82

Canadian biopharmaceutical companies 83

Cangene 83

Product portfolio 83

Pipeline portfolio 84

AEterna Zentaris 85

Product portfolio 85

Pipeline portfolio 86

Canadian market forecast, 2007–2013 87

Market forecast by ATC classes to 2013 87

Market forecast of leading brands to 2013 88

Market forecast of leading companies to 2013 90

Chapter 5 Pipeline analysis 94

Summary 94

Introduction 95

Key pipeline compounds 95

Key pipeline compound of major pharmaceutical companies 95

Telaprevir 95

Isentress 97

Prevnar 13vPnC 98

Cervarix 99

Menveo 100

Effient 101

Xarelto 102

Multaq 103

Onglyza 105

Actemra 106

Denosumab 108

Vimpat 110

Telcagepant 111

Axitinib 112

Ixempra 113

Key pipeline compounds of Canadian biopharmaceutical companies 114

Overview of issues encountered by the biopharmaceutical industry 114

Urocidin 115

DM-71 117

Dirucotide 119

Voclosporin 120

Tesamorelin 122

Market forecast of pipeline compounds to 2013 124

Chapter 6 Appendix 128

IMS Data 128

Anatomical Therapeutic Classification (ATC) 128

C: Cardiovascular system 128

N: Nervous system 128

A: Alimentary tract and metabolism 128

L: Antineoplastic and immunomodulating agents 129

J: General anti-infectives systemic 129

R: Respiratory system 129

M: Musculo-skeletal system 129

G: Genito-urinary system and sex hormones 129

B: Blood and blood forming organs 129

D: Dermatologicals 130

T: Diagnostic agents 130

H: Systemic hormonal preparations 130

S: Sensory organs 130

V: Various 130

Licensing status as per IMS Health 130

Original brand 130

Other brand 131

Licensed brand 131

Patent N/A brands 131

Unbranded/generic product 131

Glossary 132

Index 134

List of Figures

Figure 3.1: Overview of regulation of access to drugs in Canada 30

Figure 3.2: Clinical trial regulations governed by the TPD 33

Figure 3.3: Reimbursement process 40

Figure 3.4: Formulary listing 42

Figure 4.5: Pharmaceutical sales by provinces and territories, 2006–2007 52

Figure 4.6: Sales of types of brands in Canada, 2006–2007 53

Figure 4.7: Competitive analysis of Canadian market by leading therapeutic areas, 2006–2007 55

List of Tables

Table 2.1: Socioeconomic indicators, 2007 20

Table 2.2: Demographic indicators, 2007 21

Table 2.3: Forecast epidemiology in Canada 23

Table 3.4: Different forms of regulatory submission in Canada 34

Table 3.5: Review times of major drugs approved after January 2005 35

Table 3.6: PMPRB drug categories 38

Table 4.7: Canadian market by therapeutic area, 2006–2007 54

Table 4.8: Leading drug classes in the Canadian market, 2006–2007 56

Table 4.9: Leading brands in the Canadian market, 2006–2007 57

Table 4.10: Key players in the Canadian market, 2006–2007 58

Table 4.11: Ranking of companies across ATC classes in Canada by sales 2007 ($m) 59

Table 4.12: Pfizer sales by therapeutic areas, 2006–2007 61

Table 4.13: Leading brands of Pfizer, 2006–2007 62

Table 4.14: J&J sales by therapeutic areas, 2006–2007 64

Table 4.15: Leading brands of J&J, 2006–2007 66

Table 4.16: AstraZeneca sales by therapeutic areas, 2006–2007 68

Table 4.17: Leading brands of AstraZeneca, 2006–2007 69

Table 4.18: GlaxoSmithKline sales by therapeutic areas, 2006–2007 71

Table 4.19: Leading brands of GlaxoSmithKline, 2006–2007 72

Table 4.20: Novartis sales by therapeutic areas, 2006–2007 74

Table 4.21: Leading brands of Novartis, 2006–2007 75

Table 4.22: Apotex sales by therapeutic areas, 2006–2007 78

Table 4.23: Leading brands of Apotex, 2006–2007 79

Table 4.24: Novopharm sales by therapeutic areas, 2006–2007 81

Table 4.25: Leading brands of Novopharm, 2006–2007 82

Table 4.26: Pipeline portfolio of Cangene 84

Table 4.27: Pipeline portfolio of AEterna Zentaris 86

Table 4.28: ATC sales forecast, 2008–13 87

Table 4.29: Leading brands sales forecast, 2008–13 88

Table 4.30: ATC sales forecast, 2008–13 90

Table 5.31: An overview of telaprevir 95

Table 5.32: An overview of Isentress 97

Table 5.33: An overview of Prevnar 13vPnC 98

Table 5.34: An overview of Cervarix 99

Table 5.35: An overview of Menveo 100

Table 5.36: An overview of Effient 101

Table 5.37: An overview of Xarelto 102

Table 5.38: An overview of Multaq 103

Table 5.39: An overview of Onglyza 105

Table 5.40: An overview of Actemra 106

Table 5.41: An overview of denosumab 108

Table 5.42: An overview of Vimpat 110

Table 5.43: An overview of Telcagepant 111

Table 5.44: Results of Phase III trial of telcagepant in migraine 111

Table 5.45: An overview of axitinib 112

Table 5.46: An overview of Ixempra 113

Table 5.47: An overview of Urocidin 115

Table 5.48: An overview of DM-71 117

Table 5.49: An overview of Dirucotide 119

Table 5.50: An overview of voclosporin 120

Table 5.51: An overview of Tesamorelin 122

Table 5.52: Pipeline sales forecast, 2008–13 124

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/The-Canadian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities.html

The Russian Clinical trials market has always enjoyed good returns since its inception, but its growth has been especially significant over the past few years, and is expected to post major growth in the future says our new report “Clinical Trials Market in Russia”.

The number of Clinical trials conducted in Russia increased to 615 in 2008, which is an increase of around 9% over 2007. The country has a highly centralized healthcare system. It implies that the country has highly specialized medical units that deliver healthcare services to all the patients with common symptoms under one roof. The patients normally follow the references for the tests and treatments given by the doctors. These references are to the highly specialized doctors in the big hospitals.

The Russian Clinical Trials have been enjoying significant foreign investments and accounts for more than two-third of the total clinical trials across the world. Russia sponsored 201 clinical trials in 2008, followed by American sponsors who conducted 145 clinical trials during the year. The clinical trials conducted by Russia include various therapy areas such as oncology, cardiology, pulmonology, etc. The country has large number of physicians who are willing to work as Clinical Research Investigators, to enhance their knowledge in their fields of specialization and earn a subsidiary income.

The government is also taking vital steps to bring healthcare reforms and to encourage the Russian drug makers having well-laid plans for the development of innovative drugs, especially vaccines to compete in the market at par with the foreign players. It has recently invested US$ 3.4 Billion to improve the utilization of resources in the Russian Clinical Trials Market.

Our report is the outcome of the extensive research and thorough analysis of the Russia Clinical Trials Market. It covers the various market dynamics that play upon the performance of the Russia Clinical Trials Market. The report will also help the client to assess the future outlook of the industry based on the government initiatives, regulatory framework and the growth pattern of the pharmaceutical industry.
Table of Contents:

1. Analyst View
2. Clinical Trials Market Overview
3. Russian Clinical Trials Market
3.1 Foreign Participation
3.2 Clinical Research Outsourcing
4. Market Performance and Forecast
4.1 Clinical Trials
4.2 Global Clinical Trial Study
4.3 Trials in Advanced Phases
4.4 Trials under Major Therapy Areas
4.5 Multi-national Sponsors
5. Patient Enrolment
5.1 Population
5.2 Disease Profile
5.3 Patient Recruitment
5.4 Patient Recruitment Rate
6. Regulatory Environment
7. Cost Analysis
7.1 Lab Fees
7.2 Hourly Rate of CRO
8. Clinical Trials and New Drugs Approval
8.1 FDA Inspections
8.2 FDA Approved Drugs
8.3 EMEA Approved Drugs
9. Key Market Trends
10. Industry Restraints
11. Key Players
11.1 Biocad
11.2 Novartis
11.3 Sanofi-Aventis
11.4 GlaxoSmithKline plc (GSK)
11.5 Pfizer

List of Tables

Table 2-1: Drug Discovery, Development and Approval Process
Table 4-1: Number of Clinical Trials by Top Five Sponsors (2008)
Table 4-2: Clinical Trials by Top Five International Study Sponsors (2008)
Table 4-3: Clinical Trials by Top Five Russian Study Sponsors (2008)
Table 5-1: Patient Recruitment Rates in Top Five Therapeutic Areas
Table 7-1: Lab Fees Comparison with UK and US (US$)
Table 7-2: Fees Charged by Local CROs in Comparison to International CROs (US$/Hour)
Table 8-1: New Drugs Approved by FDA in Q4 2008
Table 8-2: New Drugs approved by EMEA in Q4 2008
Table 9-1: Patient Investigator Fees in Comparison to India, US and Europe (US$)
Table 9-2: Population and City Distribution by Federal Region
Table 9-3: Top Ten Emerging Cities/Region by Number of New Sites (2008)

List of Charts

Figure 2-1: Share of Europe in Global Clinical Trials Market (2008)
Figure 2-2: European Clinical Trials Market by Player (%), 2008
Figure 2-3: European Clinical Research Outsourcing Market (Billion Euro) 2008 & 2012
Figure 2-4: Share of Eastern and Western Europe in Clinical Trials Market (2008 & 2012)
Figure 3-1: Share of Russian & International Sponsors in Clinical Trials (2007 & 2008)
Figure 3-2: Clinical Trials by Type of Operator (%)
Figure 4-1: Number of Clinical Trials (2005-2008)
Figure 4-2: Forecast for Number of Clinical Trials (2009-2012)
Figure 4-3: Share of Study Type in Clinical Trials (2004 to 2007)
Figure 4-4: Share of Study Type in Clinical Trials (2007 & 2008)
Figure 4-5: Number of Clinical Trials by Phase (2007 & 2008)
Figure 4-6: Clinical Trials by Therapy Area (%) 2007 & 2008
Figure 4-7: Phases of Clinical Trials by International Sponsors (Q3 2008)
Figure 5-1: Comparison of Population with Ukraine (Million) 2007 & 2008
Figure 5-2: Population Breakup by Age Group (%), 2008
Figure 5-3: Share of Population and Clinical Trials by Region
Figure 5-4: Leading Causes of Death (%) 2005 & 2030
Figure 5-5: Patient Recruitment by Phase of Study (%), 2008
Figure 8-1: Number of FDA Inspections since 1995 to 2008
Figure 8-2: FDA Inspection Results (%), 1995 to 2007
Figure 8-3: FDA Inspection Results (%), 2008
Figure 9-1: Qualified Specialists by Type (Thousand)
Figure 9-2: Urban & Rural Population Breakup (%) 2008
Figure 9-3: Pharmaceutical Market (Billion US$) 2007-2009
Figure 9-4: Forecast for Pharmaceutical Market (Billion US$), 2010-2012
For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Clinical-Trials-Market-in-Russia.html